Solid Tumors
ACIP Recommends More Flu Vaccine Choices for Adults Who Received a Solid Organ Transplant
The ACIP said that the high-dose inactivated and adjuvanted inactivated influenza vaccines are acceptable options ...
AUGUST 9, 2024
Augtyro Approved for Adult and Pediatric Patients With NTRK Gene Fusion-Positive Solid Tumors
The FDA has granted accelerated approval to repotrectinib (Augtyro, Bristol Myers Squibb) for adult and pediatric ...
JUNE 14, 2024
Retevmo Approved for Pediatric Patients with RET-altered Metastatic Thyroid Cancer or Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Lilly.
MAY 30, 2024
Subcutaneous Injection of Nivolumab on the Horizon
Patients and clinicians may have an injectable form of the immunotherapy nivolumab (Opdivo, Bristol Myers Squibb) ...
MARCH 29, 2024
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia (denosumab) and Xgeva (denosumab). Sandoz’s ...
MARCH 6, 2024
FDA Expands Pediatric Indication for Rozlytrek and Approves New Pellet Formulation
The FDA granted accelerated approval to entrectinib (Rozlytrek, Genentech) for pediatric patients older than 1 ...
OCTOBER 24, 2023
Keytruda Granted Full Approval for MSI-H/dMMR Solid Tumors
The FDA granted full approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients ...
APRIL 3, 2023
Cell-Free DNA Test Detects Cancers Prior to Signs or Symptoms
A novel blood test appears to hold promise for detecting an array of cancers, such as hematologic malignancies and ...
NOVEMBER 7, 2022
FDA Approves Retevmo for Locally Advanced or Metastatic RET Fusion-positive Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with ...
SEPTEMBER 22, 2022
100% Remission Rate ‘Thrills’ Rectal Cancer Investigators
A phase 2 study of patients with early-stage rectal cancer, conducted at Memorial Sloan Kettering Cancer ...
JUNE 8, 2022
FDA Approves Vitrakvi for Solid Tumors With NTRK Gene Fusions
Larotrectinib is indicated for tumors that have a NTRK gene fusion without a known acquired resistance mutation, ...
NOVEMBER 30, 2018
Complex Cancer Surgery: A Complex Conversation
Surgery is well established as being of critical importance in the primary therapy of solid tumors. A number of ...
JULY 17, 2016
